8/3/2010

Memorial Sloan-Kettering Cancer Center in Manhattan created a curriculum that would train nurses in administering 3F8, a drug candidate being developed by United Therapeutics for neuroblastoma. The program would benefit a clinical trial involving 14 hospitals across the U.S.

Full Story:
Nurse.com

Related Summaries